NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

Myriad Genetics, Inc. (MYGN) Stock Analysis

Myriad Genetics, Inc. (MYGN) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MYGN

$5.57

+$0.03 (+0.54%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MYGN with… →

MYGN Key Statistics

As of Oct 21, 2026
Trading
Open
$5.59
Previous Close
$5.54
Day's Range
5.45–5.74
52-Week Range
2.74–8.50
Volume
4.89M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.64
Valuation
Market Cap
$532.77M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.24
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.18
Financials (FY)
Revenue (FY)
$824.50M−1.56%
Net Income (FY)
−$365.90M
Profit marginThe share of revenue left as profit after all costs and taxes.
−13.96%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
95.65M
1-Year Return
−30.89%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
2.46M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MYGN closed at $5.57, −30.89% over 1 year.

Myriad Genetics, Inc. (MYGN) has a market capitalization of $532.77M.

In fiscal 2025, MYGN reported revenue of $824.50M.

MYGN Stock Return by Calendar Year

Myriad Genetics, Inc. (MYGN) 10-year return: what $10,000 became

1 year
$10,000 $6,911
−30.89%
5 years
$10,000 $1,714
−82.86%
10 years
$10,000 $2,825
−71.75%

If you had invested $10,000 in Myriad Genetics, Inc. (MYGN) 10 years ago, at the close on October 21, 2016, it would have been worth $2,825 at the close on October 21, 2026: −71.75% in total, −11.88% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−9.43%
2025−55.14%
2024−28.37%
2023+31.91%
2022−47.43%
2021+39.61%
2020−27.40%
2019−6.33%
2018−15.37%
2017+106.06%
2016 (partial year)−44.41%

As of October 21, 2026.

MYGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$824.50M−$365.90M−44.4%
2024$837.60M−$127.30M−15.2%
2023$753.20M−$263.30M−35.0%
2022$678.40M−$112.00M−16.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$824.50M$576.60M−$67.80M−$365.90M−44.4%
2024$837.60M$585.40M−$88.00M−$127.30M−15.2%
2023$753.20M$517.00M−$144.60M−$263.30M−35.0%
2022$678.40M$476.40M−$123.70M−$112.00M−16.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MYGN Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricMYGNDiagnostics & Research medianvs median
P/S ratio0.665.230.1x the median
Profit margin−13.96%−0.93%13.0 pts below

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Myriad Genetics, Inc. (MYGN) at $532.77M. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 2,700.

The most recent close on file for MYGN is $5.57, dated October 21, 2026. That is +$0.03 (+0.54%) against the previous close. Over the past 52 weeks the price has ranged from $2.74 to $8.50. The latest close sits 103.28% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $824.50M. That is −1.56% against the prior fiscal year, when revenue was $837.60M. The same year closed with a net loss of $365.90M. Profit margin runs at −13.96%. That is 13 percentage points below the Diagnostics & Research median of −0.93%. Trailing earnings per share are −1.18.

Across the 4 fiscal years on file, revenue moves from $678.40M in 2022 to $824.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.24. Measured against sales, the shares trade at 0.66 times revenue. On price-to-sales that is 0.1 times the Diagnostics & Research median of 5.23. 45 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −30.89%. Across 10 years the annualized return works out at −11.88%. The reported beta is 1.64. Annualized volatility over the trailing 10 years is 67.58%.

Growth & Income

The record shows no dividend for MYGN.

2026 is still running; the total return is −9.43% year to date. The strongest complete calendar year on file is 2017 at +106.06%; the weakest is 2025 at −55.14%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Myriad Genetics, Inc. (MYGN) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Myriad Genetics, Inc. MYGN $532.77M —
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. Myriad Genetics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Myriad Genetics, Inc.

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus's gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Visit website →